Corrigendum: Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM)

Jane E Norman,[1]* Neil Marlow,[2] Claudia-Martina Messow,[3] Andrew Shennan,[4] Philip R Bennett,[5] Steven Thornton,[6] Stephen C Robson,[7] Alex McConnachie,[3] Stavros Petrou,[8] Neil J Sebire,[2] Tina Lavender,[9] Sonia Whyte[1] and John Norrie[10] for the OPPTIMUM study group

[1]Tommy's Centre for Maternal and Fetal Health, MRC Centre for Maternal and Fetal Health, University of Edinburgh, Edinburgh, UK
[2]Institute of Women's Health, University College London, London, UK
[3]Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
[4]Women's Health Academic Centre, King's College London, London, UK
[5]Obstetrics and Gynaecology, Department of Surgery and Cancer, Imperial College London, London, UK
[6]Obstetrics and Gynaecology (Barts), Queen Mary University of London, London, UK
[7]The Medical School, University of Newcastle, Newcastle, UK
[8]Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
[9]School of Nursing, University of Manchester, Manchester, UK
[10]Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, Aberdeen, UK

*Corresponding author

Corrigendum issued February 2019
Corrigendum DOI: 10.3310/hta22350-c201902
Original DOI: 10.3310/hta22350

This report should be referenced as follows:

Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, *et al*. Corrigendum: Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM). *Health Technol Assess* 2018;**22**(35). Corrigendum to *Health Technol Assess* 2019;**22**(35):305–334.

Health Technology Assessment is indexed and abstracted in *Index Medicus*/MEDLINE, *Excerpta Medica*/EMBASE, *Science Citation Index Expanded* (SciSearch®) and *Current Contents*®/ Clinical Medicine.

Corrigendum notice

Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM)

Jane E Norman, Neil Marlow, Claudia-Martina Messow, Andrew Shennan, Philip R Bennett, Steven Thornton, Stephen C Robson, Alex McConnachie, Stavros Petrou, Neil J Sebire, Tina Lavender, Sonia Whyte and John Norrie for the OPPTIMUM study group

This paper[1] is corrected as follows:

Introduction

During sharing of the data in OPPTIMUM for an individual patient data meta-analysis, a coding error became apparent in the neonatal death data described in the original report.[1] This corrigendum notice describes the errors identified.

Description of the error identified

Ten neonatal deaths, 8 in the progesterone group and 2 in the control group, were incorrectly categorised as postneonatal deaths and not as neonatal deaths in the original report.[1] Neonatal death was a component of the neonatal primary outcome. Correction of this error requires amendment of some of the tables and text in the paper, including those relating to the neonatal primary outcome.

The finding that progesterone prophylaxis did not reduce the adjusted incidence of the neonatal primary outcome is unchanged. Total deaths from trial entry to 2 years of age do not change. The overall conclusions of the study similarly do not change.

Corrected Abstract text

Page viii: the second sentence in the *Abstract, Results* has been replaced with the following text:

Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17].

Corrected Scientific summary text

Page xxix: the second sentence in the *Scientific summary, Results* has been replaced with the following text:

Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17].

Corrected tables

Page 17: *Table 6, Death, brain injury or severe chronic lung disease* rows have been amended as follows:

TABLE 6 Summaries of primary outcome measures for all patients and according to treatment groups

Outcome	All	Trial group		Adjusted OR or difference in means (95% CI)
		Placebo	Progesterone	
Death or delivery before 34 weeks				
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)	
No, *n* (%)	993 (83.0)	489 (81.9)	504 (84.0)	0.86 (0.61 to 1.22)
Yes, *n* (%)	204 (17.0)	108 (18.1)	96 (16.0)	
Death, brain injury or severe chronic lung disease				
N_{obs} (N_{miss})	1176 (50)	587 (23)	589 (27)	
No, *n* (%)	1068 (90.8)	525 (89.5)	543 (92.2)	0.72 (0.44 to 1.17)
Yes, *n* (%)	108 (9.2)	62 (10.6)	46 (7.8)	
Bayley III cognitive composite score at age 2 years (children who are alive only)				
N_{obs} (N_{miss})	833 (393)	423 (187)	410 (206)	
Mean (SD), points	99.6 (14.9)	99.5 (15.0)	99.7 (14.7)	
Median (IQR), points	100.0 (90.0–105.0)	100.0 (90.0–105.0)	100.0 (90.0–110.0)	
Range, points	55.0–149.0	55.0–149.0	55.0–145.0	
Bayley III cognitive composite score at age 2 years (scores imputed for deaths)				
N_{obs} (N_{miss})	869 (357)	439 (171)	430 (186)	
Mean (SD), points	97.5 (17.7)	97.7 (17.5)	97.3 (17.9)	–0.48 (–2.77 to 1.81)
Median (IQR), points	100.0 (90.0–105.0)	100.0 (90.0–105.0)	100.0 (90.0–105.0)	
Range, points	49.0–149.0	49.0–149.0	49.0–145.0	

CI, confidence interval; IQR, interquartile range; N_{miss}, number of women with missing data; N_{obs}, number of observations; OR, odds ratio; SD, standard deviation.

Page 18: *Table 7, Neonatal death* rows have been amended as follows:

TABLE 7 Secondary clinical outcomes, by treatment group

Outcome	All	Trial group	
		Placebo	Progesterone
Summaries of secondary outcome measures at delivery and in the neonatal period for all patients and according to treatment groups			
Gestational age at delivery (weeks)			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
Mean (SD)	36.9 (4.2)	36.8 (4.2)	36.9 (4.1)
Median (IQR)	38.3 (35.7–39.6)	38.3 (35.4–39.7)	38.1 (36.0–39.4)
Range	22.4–42.7	22.4–42.7	23.0–42.1
Delivery before 34 weeks			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	993 (83.0)	489 (81.9)	504 (84.0)
Yes, *n* (%)	204 (17.0)	108 (18.1)	96 (16.0)
Fetal death (miscarriage or stillbirth)			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	1182 (98.7)	590 (98.8)	592 (98.7)
Yes, *n* (%)	15 (1.3)	7 (1.2)	8 (1.3)
Neonatal death			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	1180 (98.6)	589 (98.7)	591 (98.5)
Yes, *n* (%)	17 (1.4)	8 (1.3)	9 (1.5)
Brain injury			
N_{obs} (N_{miss})	1158 (68)	574 (36)	584 (32)
No, *n* (%)	1106 (95.5)	540 (94.1)	566 (96.9)
Yes, *n* (%)	52 (4.5)	34 (5.9)	18 (3.1)
Severe chronic lung disease			
N_{obs} (N_{miss})	1154 (72)	574 (36)	580 (36)
No, *n* (%)	1119 (97.0)	556 (96.9)	563 (97.1)
Yes, *n* (%)	35 (3.0)	18 (3.1)	17 (2.9)
Need for surfactant administration			
N_{obs} (N_{miss})	1156 (70)	573 (37)	583 (33)
No, *n* (%)	1064 (92.0)	528 (92.1)	536 (91.9)
Yes, *n* (%)	92 (8.0)	45 (7.9)	47 (8.1)

continued

TABLE 7 Secondary clinical outcomes, by treatment group (*continued*)

Outcome	All	Trial group	
		Placebo	Progesterone
Necrotising enterocolitis			
N_{obs} (N_{miss})	1155 (71)	574 (36)	581 (35)
No, *n* (%)	1124 (97.3)	561 (97.7)	563 (96.9)
Yes, suspected, *n* (%)	16 (1.4)	5 (0.9)	11 (1.9)
Yes, medical treatment only, *n* (%)	10 (0.9)	4 (0.7)	6 (1.0)
Yes, required drain or laparotomy, *n* (%)	5 (0.4)	4 (0.7)	1 (0.2)
Infection			
N_{obs} (N_{miss})	1154 (72)	573 (37)	581 (35)
No, *n* (%)	1074 (93.1)	537 (93.7)	537 (92.4)
Yes, *n* (%)	80 (6.9)	36 (6.3)	44 (7.6)
Number of discrete episodes with positive blood culture in those with infection			
N_{obs} (N_{miss})	73 (7)	33 (3)	40 (4)
0, *n* (%)	37 (50.7)	14 (42.4)	23 (57.5)
1, *n* (%)	28 (38.4)	16 (48.5)	12 (30.0)
2, *n* (%)	7 (9.6)	3 (9.1)	4 (10.0)
4, *n* (%)	1 (1.4)	0 (0.0)	1 (2.5)
Number of discrete episodes with positive cerebrospinal fluid culture in those with infection			
N_{obs} (N_{miss})	74 (6)	34 (2)	40 (4)
0, *n* (%)	71 (95.9)	34 (100.0)	37 (92.5)
1, *n* (%)	2 (2.7)	0 (0.0)	2 (5.0)
2, *n* (%)	1 (1.4)	0 (0.0)	1 (2.5)
Highest level of care in delivery room			
N_{obs} (N_{miss})	1165 (61)	584 (26)	581 (35)
Minimal (none or tactile stimulation), *n* (%)	924 (79.3)	456 (78.1)	468 (80.6)
Intubation plus chest compressions and/or adrenaline, *n* (%)	3 (0.3)	0 (0.0)	3 (0.5)
Suction, *n* (%)	7 (0.6)	4 (0.7)	3 (0.5)
Suction and facial O_2 only, *n* (%)	39 (3.3)	19 (3.3)	20 (3.4)
Mask ventilation only, *n* (%)	100 (8.6)	56 (9.6)	44 (7.6)
Intubation, *n* (%)	86 (7.4)	47 (8.0)	39 (6.7)
Intubation plus chest compressions, *n* (%)	6 (0.5)	2 (0.3)	4 (0.7)
Number of days of normal care			
N_{obs} (N_{miss})	1151 (75)	570 (40)	581 (35)
Mean (SD)	1.7 (2.0)	1.7 (2.3)	1.7 (1.6)
Median (IQR)	1.0 (1.0–2.0)	1.0 (0.0–2.0)	1.0 (1.0–2.0)
Range	0.0–28.0	0.0–28.0	0.0–12.0

TABLE 7 Secondary clinical outcomes, by treatment group (*continued*)

Outcome	All	Trial group	
		Placebo	Progesterone
Number of days of special care			
N_{obs} (N_{miss})	1151 (75)	570 (40)	581 (35)
Mean (SD)	3.5 (9.6)	4.2 (10.6)	2.9 (8.3)
Median (IQR)	0.0 (0.0–0.0)	0.0 (0.0–1.0)	0.0 (0.0–0.0)
Range	0.0–92.0	0.0–85.0	0.0–92.0
Number of days of level 2 care			
N_{obs} (N_{miss})	1149 (77)	569 (41)	580 (36)
Mean (SD)	2.2 (9.5)	2.2 (8.4)	2.1 (10.4)
Median (IQR)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)
Range	0.0–137.0	0.0–74.0	0.0–137.0
Number of days of level 1 care			
N_{obs} (N_{miss})	1149 (77)	569 (41)	580 (36)
Mean (SD)	1.9 (7.7)	1.8 (7.3)	1.9 (8.1)
Median (IQR)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)
Range	0.0–75.0	0.0–75.0	0.0–64.0
Maternal or child serious adverse events during pregnancy and birth[a]			
N_{obs} (N_{miss})	1226 (0)	610 (0)	616 (0)
No, *n* (%)	1097 (89.5)	540 (88.5)	557 (90.4)
Yes, *n* (%)	129 (10.5)	70 (11.5)	59 (9.6)
Death or moderate/severe neurodevelopmental impairment			
N_{obs} (N_{miss})	818 (408)	419 (191)	399 (217)
No, *n* (%)	700 (85.6)	368 (87.8)	332 (83.2)
Yes, *n* (%)	118 (14.4)	51 (12.2)	67 (16.8)
Moderate/severe neurodevelopmental impairment			
N_{obs} (N_{miss})	782 (444)	403 (207)	379 (237)
No, *n* (%)	700 (89.5)	368 (91.3)	332 (87.6)
Yes, *n* (%)	82 (10.5)	35 (8.7)	47 (12.4)
Components of neurodevelopmental disability			
Motor			
N_{obs} (N_{miss})	917 (309)	456 (154)	461 (155)
No, *n* (%)	909 (99.1)	452 (99.1)	457 (99.1)
Yes, *n* (%)	8 (0.9)	4 (0.9)	4 (0.9)
Cognitive function			
N_{obs} (N_{miss})	913 (313)	452 (158)	461 (155)
No, *n* (%)	876 (95.9)	434 (96.0)	442 (95.9)
Yes, *n* (%)	37 (4.1)	18 (4.0)	19 (4.1)

continued

TABLE 7 Secondary clinical outcomes, by treatment group (*continued*)

Outcome	All	Trial group	
		Placebo	Progesterone
Hearing			
N_{obs} (N_{miss})	931 (295)	465 (145)	466 (150)
No, *n* (%)	928 (99.7)	463 (99.6)	465 (99.8)
Yes, *n* (%)	3 (0.3)	2 (0.4)	1 (0.2)
Speech and language			
N_{obs} (N_{miss})	891 (335)	446 (164)	445 (171)
No, *n* (%)	859 (96.4)	432 (96.9)	427 (96.0)
Yes, *n* (%)	32 (3.6)	14 (3.1)	18 (4.0)
Vision			
N_{obs} (N_{miss})	913 (313)	466 (144)	447 (169)
No, *n* (%)	909 (99.6)	462 (99.1)	447 (100.0)
Yes, *n* (%)	4 (0.4)	4 (0.9)	0 (0.0)
Respiratory			
N_{obs} (N_{miss})	847 (379)	434 (176)	413 (203)
No, *n* (%)	837 (98.8)	431 (99.3)	406 (98.3)
Yes, *n* (%)	10 (1.2)	3 (0.7)	7 (1.7)
Gastrointestinal			
N_{obs} (N_{miss})	844 (382)	432 (178)	412 (204)
No, *n* (%)	831 (98.5)	428 (99.1)	403 (97.8)
Yes, *n* (%)	13 (1.5)	4 (0.9)	9 (2.2)
Renal			
N_{obs} (N_{miss})	848 (378)	434 (176)	414 (202)
No, *n* (%)	844 (99.5)	433 (99.8)	411 (99.3)
Yes, *n* (%)	4 (0.5)	1 (0.2)	3 (0.7)
Admitted to hospital			
N_{obs} (N_{miss})	850 (376)	434 (176)	416 (200)
No, *n* (%)	751 (88.4)	383 (88.2)	368 (88.5)
Yes, *n* (%)	99 (11.6)	51 (11.8)	48 (11.5)
Admitted to hospital for respiratory reason			
N_{obs} (N_{miss})	127 (1099)	63 (547)	64 (552)
No, *n* (%)	79 (62.2)	39 (61.9)	40 (62.5)
Yes, *n* (%)	48 (37.8)	24 (38.1)	24 (37.5)
Admitted to hospital for surgery			
N_{obs} (N_{miss})	118 (1108)	56 (554)	62 (554)
No, *n* (%)	96 (81.4)	49 (87.5)	47 (75.8)
Yes, *n* (%)	22 (18.6)	7 (12.5)	15 (24.2)

TABLE 7 Secondary clinical outcomes, by treatment group (*continued*)

Outcome	All	Trial group	
		Placebo	Progesterone
Admitted to hospital for other reason			
N_{obs} (N_{miss})	119 (1107)	56 (554)	63 (553)
No, *n* (%)	92 (77.3)	43 (76.8)	49 (77.8)
Yes, *n* (%)	27 (22.7)	13 (23.2)	14 (22.2)
Number of hospitalisations			
N_{obs} (N_{miss})	858 (368)	437 (173)	421 (195)
0, *n* (%)	750 (87.4)	386 (88.3)	364 (86.5)
1, *n* (%)	87 (10.1)	42 (9.6)	45 (10.7)
2, *n* (%)	15 (1.7)	5 (1.1)	10 (2.4)
3, *n* (%)	2 (0.2)	2 (0.5)	0 (0.0)
4, *n* (%)	2 (0.2)	1 (0.2)	1 (0.2)
7, *n* (%)	1 (0.1)	1 (0.2)	0 (0.0)
11, *n* (%)	1 (0.1)	0 (0.0)	1 (0.2)
Summaries of secondary outcome measures at 2-year follow-up for all patients and according to treatment groups: SDQ			
Emotional problems scale			
N_{obs} (N_{miss})	669 (557)	341 (269)	328 (288)
Mean (SD)	1.1 (1.2)	1.1 (1.2)	1.1 (1.2)
Median (IQR)	1.0 (0.0–2.0)	1.0 (0.0–1.0)	1.0 (0.0–2.0)
Range	0.0–10.0	0.0–10.0	0.0–7.0
Conduct problems scale			
N_{obs} (N_{miss})	668 (558)	342 (268)	326 (290)
Mean (SD)	2.6 (1.8)	2.7 (1.8)	2.6 (1.8)
Median (IQR)	2.0 (1.0–4.0)	2.0 (1.0–4.0)	2.0 (1.0–3.8)
Range	0.0–10.0	0.0–10.0	0.0–8.0
Hyperactivity scale			
N_{obs} (N_{miss})	649 (577)	334 (276)	315 (301)
Mean (SD)	4.3 (2.3)	4.2 (2.4)	4.5 (2.3)
Median (IQR)	4.0 (3.0–6.0)	4.0 (2.0–6.0)	4.0 (3.0–6.0)
Range	0.0–10.0	0.0–10.0	0.0–10.0
Peer problems scale			
N_{obs} (N_{miss})	663 (563)	345 (265)	318 (298)
Mean (SD)	2.0 (1.6)	2.0 (1.7)	2.1 (1.6)
Median (IQR)	2.0 (1.0–3.0)	2.0 (1.0–3.0)	2.0 (1.0–3.0)
Range	0.0–7.0	0.0–7.0	0.0–7.0

continued

TABLE 7 Secondary clinical outcomes, by treatment group (*continued*)

Outcome	All	Trial group	
		Placebo	Progesterone
Prosocial scale			
N_{obs} (N_{miss})	659 (567)	339 (271)	320 (296)
Mean (SD)	6.1 (2.2)	6.3 (2.2)	5.9 (2.3)
Median (IQR)	6.0 (5.0–8.0)	6.0 (5.0–8.0)	6.0 (4.0–8.0)
Range	0.0–10.0	0.0–10.0	0.0–10.0
Total difficulties scale			
N_{obs} (N_{miss})	597 (629)	302 (308)	295 (321)
Mean (SD)	10.0 (4.9)	9.8 (4.9)	10.2 (4.9)
Median (IQR)	9.0 (7.0–12.0)	9.0 (6.0–12.0)	9.0 (7.0–13.0)
Range	0.0–30.0	0.0–30.0	0.0–30.0
Impact scale			
N_{obs} (N_{miss})	828 (398)	424 (186)	404 (212)
Mean (SD)	0.2 (1.1)	0.2 (1.0)	0.2 (1.2)
Median (IQR)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)
Range	0.0–10.0	0.0–10.0	0.0–10.0

IQR, interquartile range; N_{miss}, number of women with missing data; N_{obs}, number of observations; SD, standard deviation; SDQ, Strengths and Difficulties Questionnaire.
a Up to and including day 1 after birth.

Page 32: *Table 14, Death neonatal* row has been amended as follows:

TABLE 14 Patients with at least one SAE by System Organ Class and preferred term

Type of SAE	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Number of patients, *n*	1183	590	593
Blood and lymphatic system disorders	1 (0.1)	1 (0.2)	0 (0.0)
Thrombocytopenia	1 (0.1)	1 (0.2)	0 (0.0)
Congenital, familial and genetic disorders	19 (1.6)	8 (1.4)	11 (1.9)
Cardiac septal defect	1 (0.1)	1 (0.2)	0 (0.0)
Cleft lip and palate	1 (0.1)	0 (0.0)	1 (0.2)
Congenital central nervous system anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Congenital oesophageal anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Cryptorchism	1 (0.1)	0 (0.0)	1 (0.2)
Cystic fibrosis	1 (0.1)	1 (0.2)	0 (0.0)
Dacryostenosis congenital	1 (0.1)	0 (0.0)	1 (0.2)
Hip dysplasia	1 (0.1)	1 (0.2)	0 (0.0)
Holoprosencephaly	1 (0.1)	0 (0.0)	1 (0.2)
Hydrocele	1 (0.1)	1 (0.2)	0 (0.0)
Hypospadias	2 (0.2)	0 (0.0)	2 (0.3)

TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (*continued*)

Type of SAE	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Kidney malformation	1 (0.1)	0 (0.0)	1 (0.2)
Oculoauriculovertebral dysplasia	1 (0.1)	1 (0.2)	0 (0.0)
Patent ductus arteriosus	2 (0.2)	2 (0.3)	0 (0.0)
Polydactyly	2 (0.2)	0 (0.0)	2 (0.3)
Pulmonary artery stenosis congenital	1 (0.1)	1 (0.2)	0 (0.0)
Gastrointestinal disorders	8 (0.7)	8 (1.4)	0 (0.0)
Abdominal pain	2 (0.2)	2 (0.3)	0 (0.01)
Ileus paralytic	1 (0.1)	1 (0.2)	0 (0.0)
Inguinal hernia	1 (0.2)	1 (0.2)	0 (0.0)
Necrotising colitis	2 (0.2)	2 (0.3)	0 (0.0)
Necrotising enterocolitis neonatal	3 (0.3)	3 (0.5)	0 (0.0)
General disorders and administration site conditions	4 (0.3)	2 (0.3)	2 (0.3)
Adverse drug reaction	1 (0.1)	1 (0.2)	0 (0.0)
Death neonatal	17 (1.4)	8 (1.3)	9 (1.5)
Infections and infestations	17 (1.4)	8 (1.4)	9 (1.5)
Appendicitis	1 (0.1)	1 (0.2)	0 (0.0)
Bacterial sepsis	2 (0.2)	0 (0.0)	2 (0.3)
Bronchiolitis	1 (0.1)	0 (0.0)	1 (0.2)
Bronchopneumonia	1 (0.1)	0 (0.0)	1 (0.2)
Infection	1 (0.1)	1 (0.2)	0 (0.0)
Lower respiratory tract infection	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis bacterial	1 (0.1)	1 (0.2)	0 (0.0)
Rash pustular	2 (0.2)	1 (0.2)	1 (0.2)
Sepsis	4 (0.3)	2 (0.3)	2 (0.3)
Urinary tract infection	3 (0.3)	1 (0.2)	2 (0.3)
Wound infection	1 (0.1)	0 (0.0)	1 (0.2)
Injury, poisoning and procedural complications	4 (0.3)	1 (0.2)	3 (0.5)
Post-lumbar puncture syndrome	2 (0.2)	0 (0.0)	2 (0.3)
Post-procedural complication	1 (0.1)	1 (0.2)	0 (0.0)
Uterine rupture	1 (0.1)	0 (0.0)	1 (0.2)
Investigations	5 (0.4)	2 (0.3)	3 (0.5)
Echocardiogram abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Echography abnormal	1 (0.1)	1 (0.2)	0 (0.0)
Fetal heart rate abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Weight decreased	2 (0.2)	1 (0.2)	1 (0.2)
Metabolism and nutrition disorders	4 (0.3)	3 (0.5)	1 (0.2)
Gestational diabetes	1 (0.1)	1 (0.2)	0 (0.0)
Hypoglycaemia	3 (0.3)	2 (0.3)	1 (0.2)

continued

TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (*continued*)

Type of SAE	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Neoplasms benign, malignant and unspecified (including cysts and polyps)	3 (0.3)	1 (0.2)	2 (0.3)
Breast cancer	1 (0.1)	1 (0.2)	0 (0.0)
Haemangioma of skin	1 (0.1)	0 (0.0)	1 (0.2)
Teratoma	1 (0.1)	0 (0.0)	1 (0.2)
Nervous system disorders	4 (0.3)	4 (0.7)	0 (0.0)
Cerebral ventricle dilatation	2 (0.2)	2 (0.3)	0 (0.0)
Hydrocephalus	1 (0.1)	1 (0.2)	0 (0.0)
Migraine	1 (0.1)	1 (0.2)	0 (0.0)
Pregnancy, puerperium and perinatal conditions	83 (7.0)	44 (7.5)	39 (6.6)
Amniorrhexis	3 (0.3)	3 (0.5)	0 (0.0)
Antepartum haemorrhage	9 (0.8)	5 (0.8)	4 (0.7)
Complication of pregnancy	1 (0.1)	1 (0.2)	0 (0.0)
Eclampsia	1 (0.1)	1 (0.2)	0 (0.0)
Fetal growth restriction	1 (0.1)	1 (0.2)	0 (0.0)
Fetal hypokinesia	2 (0.2)	1 (0.2)	1 (0.2)
Intrauterine death	9 (0.8)	4 (0.7)	5 (0.8)
Jaundice neonatal	1 (0.1)	1 (0.2)	0 (0.0)
Oligohydramnios	1 (0.1)	0 (0.0)	1 (0.2)
Placenta praevia haemorrhage	1 (0.1)	0 (0.0)	1 (0.2)
Post-partum haemorrhage	33 (2.8)	17 (2.9)	16 (2.7)
Pre-eclampsia	1 (0.1)	1 (0.2)	0 (0.0)
Premature baby	13 (1.1)	7 (1.2)	6 (1.0)
Premature labour	4 (0.3)	3 (0.5)	1 (0.2)
Premature rupture of membranes	3 (0.3)	1 (0.2)	2 (0.3)
Premature separation of placenta	4 (0.3)	3 (0.5)	1 (0.2)
Retained placenta or membranes	1 (0.1)	0 (0.0)	1 (0.2)
Stillbirth	2 (0.2)	0 (0.0)	2 (0.3)
Threatened labour	4 (0.3)	1 (0.2)	3 (0.5)
Uterine contractions during pregnancy	2 (0.2)	1 (0.2)	1 (0.2)
Renal and urinary disorders	1 (0.1)	1 (0.2)	0 (0.0)
Pyelocaliectasis	1 (0.1)	1 (0.2)	0 (0.0)
Reproductive system and breast disorders	10 (0.8)	6 (1.0)	4 (0.7)
Chordee	1 (0.1)	0 (0.0)	1 (0.2)
Coital bleeding	1 (0.1)	1 (0.2)	0 (0.0)
Uterine atony	1 (0.1)	0 (0.0)	1 (0.2)
Vaginal haemorrhage	7 (0.6)	5 (0.8)	2 (0.3)

TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (*continued*)

Type of SAE	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Respiratory, thoracic and mediastinal disorders	6 (0.5)	2 (0.3)	4 (0.7)
Bronchopulmonary dysplasia	1 (0.1)	0 (0.0)	1 (0.2)
Cyanosis neonatal	1 (0.1)	1 (0.2)	0 (0.0)
Grunting	1 (0.1)	0 (0.0)	1 (0.2)
Neonatal asphyxia	1 (0.1)	0 (0.0)	1 (0.2)
Pneumothorax	1 (0.1)	0 (0.0)	1 (0.2)
Transient tachypnoea of the newborn	1 (0.1)	1 (0.2)	0 (0.0)
Skin and subcutaneous tissue disorders	1 (0.1)	1 (0.2)	0 (0.0)
Rash	1 (0.1)	1 (0.2)	0 (0.0)
Surgical and medical procedures	6 (0.5)	5 (0.8)	1 (0.2)
Caesarean section	1 (0.1)	1 (0.2)	0 (0.0)
Mechanical ventilation	1 (0.1)	1 (0.2)	0 (0.0)
Patent ductus arteriosus repair	1 (0.1)	0 (0.0)	1 (0.2)
Spinal decompression	1 (0.1)	1 (0.2)	0 (0.0)
Steroid therapy	1 (0.1)	1 (0.2)	0 (0.0)
Surgery	1 (0.1)	1 (0.2)	0 (0.0)
Vascular disorders	2 (0.2)	1 (0.2)	1 (0.2)
Deep-vein thrombosis	1 (0.1)	1 (0.2)	0 (0.0)
Essential hypertension	1 (0.1)	0 (0.0)	1 (0.2)

Page 45: *Table 18, Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n = *1176)* rows have been amended as follows:

TABLE 18 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to risk group (fibronectin status)

Risk group	OR (progesterone vs. placebo)	95% CI	*p*-value	*p*-value for interaction
Primary obstetric outcome (death or delivery before 34 weeks' gestation). Interaction model (*n* = 1197)				
Low, negative fFN (*n* = 859)	0.88	0.58 to 1.33	0.542	0.907
High, positive fFN (*n* = 338)	0.91	0.57 to 1.46	0.707	
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n* = 1176)				
Low, negative fFN (*n* = 847)	0.56	0.19 to 1.70	0.310	0.55
High, positive fFN (*n* = 329)	0.87	0.36 to 2.08	0.747	
Risk group	**Expected mean difference (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Primary childhood outcome (Bayley III cognitive composite score adjusted for previous pregnancy). Interaction model (*n* = 869)				
Low, negative fFN (*n* = 628)	–0.63	–3.28 to 2.03	0.644	0.858
High, positive fFN (*n* = 241)	–1.09	–5.41 to 3.23	0.621	

Page 45: *Table 19, Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n = 682)* rows have been amended as follows:

TABLE 19 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to cervical length (≤ 25 mm) at baseline

Cervical length at baseline (mm)	OR (progesterone vs. placebo)	95% CI	*p*-value	*p*-value for interaction
Primary obstetric outcome (death or delivery before 34 weeks' gestation). Interaction model (*n* = 696)				
> 25 (*n* = 445)	0.88	0.50 to 1.57	0.672	0.542
≤ 25 (*n* = 251)	0.69	0.39 to 1.20	0.191	
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n* = 682)				
> 25 (*n* = 436)	0.86	0.42 to 1.74	0.690	0.38
≤ 25 (*n* = 246)	0.54	0.26 to 1.15	0.112	
Cervical length at baseline (mm)	**Expected mean difference (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Primary childhood outcome (Bayley III cognitive composite score adjusted for previous pregnancy). Interaction model (*n* = 496)				
> 25 (*n* = 317)	–2.27	–6.10 to 1.56	0.247	0.971
≤ 25 (*n* = 179)	–2.15	–7.23 to 2.93	0.408	

Page 46: *Table 20, Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n = *682)* rows have been amended as follows:

TABLE 20 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to cervical length (< 15 mm) at baseline

Cervical length at baseline (mm)	OR (progesterone vs. placebo)	95% CI	*p*-value	*p*-value for interaction
Primary obstetric outcome (death or delivery before 34 weeks' gestation). Interaction model (*n* = 696)				
> 15 (*n* = 599)	0.77	0.48 to 1.23	0.274	0.727
≤ 15 (*n* = 97)	0.91	0.41 to 2.04	0.819	
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n* = 682)				
> 15 (*n* = 588)	0.82	0.44 to 1.52	0.526	0.39
≤ 15 (*n* = 94)	0.49	0.18 to 1.32	0.158	
Cervical length at baseline (mm)	**Expected mean difference (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Primary childhood outcome (Bayley III cognitive composite score adjusted for previous pregnancy). Interaction model (*n* = 496)				
> 15 (*n* = 423)	–2.49	–5.77 to 0.78	0.137	0.680
≤ 15 (*n* = 73)	–0.69	–8.60 to 7.22	0.865	

Page 46: *Table 21, Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n = *1156*) rows have been amended as follows:

TABLE 21 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to history of spontaneous preterm birth

History of spontaneous preterm birth	OR (progesterone vs. placebo)	95% CI	*p*-value	*p*-value for interaction
Primary obstetric outcome (death or delivery before 34 weeks' gestation). Interaction model (*n* = 1176)				
No (*n* = 273)	0.99	0.51 to 1.92	0.972	0.62
Yes (*n* = 903)	0.82	0.58 to 1.16	0.254	
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n* = 1156)				
No (*n* = 270)	1.23	0.54 to 2.77	0.623	0.15
Yes (*n* = 886)	0.60	0.37 to 0.96	0.033	
History of spontaneous preterm birth	**Expected mean difference (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Primary childhood outcome (Bayley III cognitive composite score adjusted for previous pregnancy). Interaction model (*n* = 857)				
No (*n* = 201)	–1.11	–5.96 to 3.73	0.653	0.73
Yes (*n* = 656)	–0.14	–2.79 to 2.52	0.919	

Page 47: *Table 22, Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n = *171)* rows have been amended as follows:

TABLE 22 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to chorioamnionitis diagnosed on pathology

Chorioamnionitis diagnosed on pathology	OR (progesterone vs. placebo)	95% CI	*p*-value	*p*-value for interaction
Primary obstetric outcome (death or delivery before 34 weeks' gestation). Interaction model (*n* = 172)				
No	1.38	0.55 to 3.45	0.497	0.547
Yes (*n* = 57)	2.17	0.68 to 6.85	0.190	
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (*n* = 171)				
No	1.18	0.30 to 4.68	0.810	0.43
Yes (*n* = 56)	2.53	0.71 to 9.06	0.156	
Chorioamnionitis diagnosed on pathology	**Expected mean difference (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Primary childhood outcome (Bayley III cognitive composite score adjusted for previous pregnancy). Interaction model (*n* = 124)				
No (*n* = 81)	–2.30	–10.30 to 5.70	0.575	0.859
Yes (*n* = 43)	–1.08	–11.91 to 9.76	0.846	

Page 53: *Chapter 7 Discussion and overall conclusions*, paragraph 2, final sentence has been amended as follows:

In subgroup analyses, none of the *p*-values of any of the interaction terms approached statistical significance; in other words, we found no evidence that progesterone is any more effective in any subgroup.

Page 54: *Chapter 7 Discussion and overall conclusions*, first paragraph on p. 54 has been deleted.

Page 125: *Table 57, Death, brain injury or severe chronic lung disease* rows have been amended as follows:

TABLE 57 Summaries of primary outcome measures for all patients and according to treatment groups

		Trial group	
Parameter	**All**	**Placebo**	**Progesterone**
Death or delivery before 34 weeks' gestation			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	993 (83.0)	489 (81.9)	504 (84.0)
Yes, *n* (%)	204 (17.0)	108 (18.1)	96 (16.0)
Death, brain injury or severe chronic lung disease			
N_{obs} (N_{miss})	1176 (50)	587 (23)	589 (27)
No, *n* (%)	1068 (90.8)	525 (89.4)	543 (92.2)
Yes, *n* (%)	108 (9.2)	62 (10.6)	46 (7.8)
Bayley III cognitive composite score at 2 years			
N_{obs} (N_{miss})	833 (393)	423 (187)	410 (206)
Mean (SD)	99.6 (14.9)	99.5 (15.0)	99.7 (14.7)
Median (IQR)	100.0 (90.0–105.0)	100.0 (90.0–105.0)	100.0 (90.0–110.0)
Range	55.0–149.0	55.0–149.0	55.0–145.0
Bayley III cognitive composite score at 2 years (imputed)			
N_{obs} (N_{miss})	869 (357)	439 (171)	430 (186)
Mean (SD)	97.5 (17.7)	97.7 (17.5)	97.3 (17.9)
Median (IQR)	100.0 (90.0–105.0)	100.0 (90.0–105.0)	100.0 (90.0–105.0)
Range	49.0–149.0	49.0–149.0	49.0–145.0
Alive at 2 years			
N_{obs} (N_{miss})	1009 (217)	509 (101)	500 (116)
No, *n* (%)	36 (3.6)	16 (3.1)	20 (4.0)
Yes, *n* (%)	973 (96.4)	493 (96.9)	480 (96.0)
Survival (days)			
N_{obs} (N_{miss})	1198 (28)	598 (12)	600 (16)
Deaths median time	36,756.00	16,759.00	20,751.00
Range	1–1335	1–1331	1–1335

IQR, interquartile range; N_{miss}, number of women with missing data; N_{obs}, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:02 2015.

Page 126: *Table 58, Neonatal death* rows have been amended as follows:

TABLE 58 Summaries of secondary outcome measures at delivery/neonatal for all patients and according to treatment groups (part 1)

		Trial group	
	All	Placebo	Progesterone
Gestational age at delivery (weeks)			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
Mean (SD)	36.9 (4.2)	36.8 (4.2)	36.9 (4.1)
Median (IQR)	38.3 (35.7–39.6)	38.3 (35.4–39.7)	38.1 (36.0–39.4)
Range	22.4–42.7	22.4–42.7	23.0–42.1
Delivery before 34 weeks' gestation			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	993 (83.0)	489 (81.9)	504 (84.0)
Yes, *n* (%)	204 (17.0)	108 (18.1)	96 (16.0)
Fetal death (miscarriage or stillbirth)			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	1182 (98.7)	590 (98.8)	592 (98.7)
Yes, *n* (%)	15 (1.3)	7 (1.2)	8 (1.3)
Neonatal death			
N_{obs} (N_{miss})	1197 (29)	597 (13)	600 (16)
No, *n* (%)	1180 (98.6)	589 (98.7)	590 (98.3)
Yes, *n* (%)	17 (1.4)	8 (1.3)	9 (1.5)
Brain injury			
N_{obs} (N_{miss})	1158 (68)	574 (36)	584 (32)
No, *n* (%)	1106 (95.5)	540 (94.1)	566 (96.9)
Yes, *n* (%)	52 (4.5)	34 (5.9)	18 (3.1)
Severe chronic lung disease			
N_{obs} (N_{miss})	1154 (72)	574 (36)	580 (36)
No, *n* (%)	1119 (97.0)	556 (96.9)	563 (97.1)
Yes, *n* (%)	35 (3.0)	18 (3.1)	17 (2.9)
Need for surfactant administration			
N_{obs} (N_{miss})	1156 (70)	573 (37)	583 (33)
No, *n* (%)	1064 (92.0)	528 (92.1)	536 (91.9)
Yes, *n* (%)	92 (8.0)	45 (7.9)	47 (8.1)
Necrotising enterocolitis			
N_{obs} (N_{miss})	1155 (71)	574 (36)	581 (35)
No, *n* (%)	1124 (97.3)	561 (97.7)	563 (96.9)
Yes suspected, *n* (%)	16 (1.4)	5 (0.9)	11 (1.9)
Yes medical treatment only, *n* (%)	10 (0.9)	4 (0.7)	6 (1.0)
Yes required drain or laparotomy, *n* (%)	5 (0.4)	4 (0.7)	1 (0.2)

continued

TABLE 58 Summaries of secondary outcome measures at delivery/neonatal for all patients and according to treatment groups (part 1) (*continued*)

	All	Trial group	
		Placebo	Progesterone
Infection			
N_{obs} (N_{miss})	1154 (72)	573 (37)	581 (35)
No, *n* (%)	1074 (93.1)	537 (93.7)	537 (92.4)
Yes, *n* (%)	80 (6.9)	36 (6.3)	44 (7.6)
Number of discrete episodes with positive blood culture in those with infection			
N_{obs} (N_{miss})	73 (7)	33 (3)	40 (4)
Zero, *n* (%)	37 (50.7)	14 (42.4)	23 (57.5)
One, *n* (%)	28 (38.4)	16 (48.5)	12 (30.0)
Two, *n* (%)	7 (9.6)	3 (9.1)	4 (10.0)
Four, *n* (%)	1 (1.4)	0 (0.0)	1 (2.5)
Number of discrete episodes with positive cerebrospinal fluid culture in those with infection			
N_{obs} (N_{miss})	74 (6)	34 (2)	40 (4)
Zero, *n* (%)	71 (95.9)	34 (100.0)	37 (92.5)
One, *n* (%)	2 (2.7)	0 (0.0)	2 (5.0)
Two, *n* (%)	1 (1.4)	0 (0.0)	1 (2.5)

IQR, interquartile range; N_{miss}, number of women with missing data; N_{obs}, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:02 2015.

Page 140: *Table 71* has been amended as follows:

TABLE 71 Mixed effects logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and study centre as a random effect

Parameter	OR	95% CI	*p*-value
Treatment (progesterone vs. placebo)	0.72	0.48 to 1.07	0.104
Previous pregnancy of ≥ 14 weeks' gestation	1.50	0.48 to 2.74	0.757
n = 869			

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:07 2015.

Page 148: *Table 84, Death neonatal* row has been amended as follows:

TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Number of patients, *n*	1183	590	593
Blood and lymphatic system disorders	1 (0.1)	1 (0.2)	0 (0.0)
Thrombocytopenia	1 (0.1)	1 (0.2)	0 (0.0)

TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Congenital, familial and genetic disorders	19 (1.6)	8 (1.4)	11 (1.9)
Cardiac septal defect	1 (0.1)	1 (0.2)	0 (0.0)
Cleft lip and palate	1 (0.1)	0 (0.0)	1 (0.2)
Congenital central nervous system anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Congenital oesophageal anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Cryptorchism	1 (0.1)	0 (0.0)	1 (0.2)
Cystic fibrosis	1 (0.1)	1 (0.2)	0 (0.0)
Dacryostenosis congenital	1 (0.1)	0 (0.0)	1 (0.2)
Hip dysplasia	1 (0.1)	1 (0.2)	0 (0.0)
Holoprosencephaly	1 (0.1)	0 (0.0)	1 (0.2)
Hydrocele	1 (0.1)	1 (0.2)	0 (0.0)
Hypospadias	2 (0.2)	0 (0.0)	2 (0.3)
Kidney malformation	1 (0.1)	0 (0.0)	1 (0.2)
Oculoauriculovertebral dysplasia	1 (0.1)	1 (0.2)	0 (0.0)
Patent ductus arteriosus	2 (0.2)	2 (0.3)	0 (0.0)
Polydactyly	2 (0.2)	0 (0.0)	2 (0.3)
Pulmonary artery stenosis congenital	1 (0.1)	1 (0.2)	0 (0.0)
Gastrointestinal disorders	8 (0.7)	8 (1.4)	0 (0.0)
Abdominal pain	2 (0.2)	2 (0.3)	0 (0.0)
Ileus paralytic	1 (0.1)	1 (0.2)	0 (0.0)
Inguinal hernia	1 (0.1)	1 (0.2)	0 (0.0)
Necrotising colitis	2 (0.2)	2 (0.3)	0 (0.0)
Necrotising enterocolitis neonatal	3 (0.3)	3 (0.5)	0 (0.0)
General disorders and administration site conditions	4 (0.3)	2 (0.3)	2 (0.3)
Adverse drug reaction	1 (0.1)	1 (0.2)	0 (0.0)
Death neonatal	17 (1.4)	8 (1.3)	9 (1.5)
Infections and infestations	17 (1.4)	8 (1.4)	9 (1.5)
Appendicitis	1 (0.1)	1 (0.2)	0 (0.0)
Bacterial sepsis	2 (0.2)	0 (0.0)	2 (0.3)
Bronchiolitis	1 (0.1)	0 (0.0)	1 (0.2)
Bronchopneumonia	1 (0.1)	0 (0.0)	1 (0.2)
Infection	1 (0.1)	1 (0.2)	0 (0.0)
Lower respiratory tract infection	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis bacterial	1 (0.1)	1 (0.2)	0 (0.0)
Rash pustular	2 (0.2)	1 (0.2)	1 (0.2)

continued

TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Sepsis	4 (0.3)	2 (0.3)	2 (0.3)
Urinary tract infection	3 (0.3)	1 (0.2)	2 (0.3)
Wound infection	1 (0.1)	0 (0.0)	1 (0.2)
Injury, poisoning and procedural complications	4 (0.3)	1 (0.2)	3 (0.5)
Post-lumbar puncture	2 (0.2)	0 (0.0)	2 (0.3)
Syndrome post-procedural complication	1 (0.1)	1 (0.2)	0 (0.0)
Uterine rupture	1 (0.1)	0 (0.0)	1 (0.2)
Investigations	5 (0.4)	2 (0.3)	3 (0.5)
Echocardiogram abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Echography abnormal	1 (0.1)	1 (0.2)	0 (0.0)
Fetal heart rate abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Weight decreased	2 (0.2)	1 (0.2)	1 (0.2)
Metabolism and nutrition disorders	4 (0.3)	3 (0.5)	1 (0.2)
Gestational diabetes	1 (0.1)	1 (0.2)	0 (0.0)
Hypoglycaemia	3 (0.3)	2 (0.3)	1 (0.2)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	3 (0.3)	1 (0.2)	2 (0.3)
Breast cancer	1 (0.1)	1 (0.2)	0 (0.0)
Haemangioma of skin	1 (0.1)	0 (0.0)	1 (0.2)
Teratoma	1 (0.1)	0 (0.0)	1 (0.2)
Nervous system disorders	4 (0.3)	4 (0.7)	0 (0.0)
Cerebral ventricle dilatation	2 (0.2)	2 (0.3)	0 (0.0)
Hydrocephalus	1 (0.1)	1 (0.2)	0 (0.0)
Migraine	1 (0.1)	1 (0.2)	0 (0.0)
Pregnancy, puerperium and perinatal conditions	83 (7.0)	44 (7.5)	39 (6.6)
Amniorrhexis	3 (0.3)	3 (0.5)	0 (0.0)
Antepartum haemorrhage	9 (0.8)	5 (0.8)	4 (0.7)
Complication of pregnancy	1 (0.1)	1 (0.2)	0 (0.0)
Eclampsia	1 (0.1)	1 (0.2)	0 (0.0)
Fetal growth restriction	1 (0.1)	1 (0.2)	0 (0.0)
Fetal hypokinesia	2 (0.2)	1 (0.2)	1 (0.2)
Intrauterine death	9 (0.8)	4 (0.7)	5 (0.8)
Jaundice neonatal	1 (0.1)	1 (0.2)	0 (0.0)
Oligohydramnios	1 (0.1)	0 (0.0)	1 (0.2)
Placenta praevia haemorrhage	1 (0.1)	0 (0.0)	1 (0.2)
Post-partum haemorrhage	33 (2.8)	17 (2.9)	16 (2.7)
Pre-eclampsia	1 (0.1)	1 (0.2)	0 (0.0)

TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Premature baby	13 (1.1)	7 (1.2)	6 (1.0)
Premature labour	4 (0.3)	3 (0.5)	1 (0.2)
Premature rupture of membranes	3 (0.3)	1 (0.2)	2 (0.3)
Premature separation of placenta	4 (0.3)	3 (0.5)	1 (0.2)
Retained placenta or membranes	1 (0.1)	0 (0.0)	1 (0.2)
Stillbirth	2 (0.2)	0 (0.0)	2 (0.3)
Threatened labour	4 (0.3)	1 (0.2)	3 (0.5)
Uterine contractions during pregnancy	2 (0.2)	1 (0.2)	1 (0.2)
Renal and urinary disorders	1 (0.1)	1 (0.2)	0 (0.0)
Pyelocaliectasis	1 (0.1)	1 (0.2)	0 (0.0)
Reproductive system and breast disorders	10 (0.8)	6 (1.0)	4 (0.7)
Chordee	1 (0.1)	0 (0.0)	1 (0.2)
Coital bleeding	1 (0.1)	1 (0.2)	0 (0.0)
Cterine atony	1 (0.1)	0 (0.0)	1 (0.2)
Vaginal haemorrhage	7 (0.6)	5 (0.8)	2 (0.3)
Respiratory, thoracic and mediastinal disorders	6 (0.5)	2 (0.3)	4 (0.7)
Bronchopulmonary dysplasia	1 (0.1)	0 (0.0)	1 (0.2)
Cyanosis neonatal	1 (0.1)	1 (0.2)	0 (0.0)
Grunting	1 (0.1)	0 (0.0)	1 (0.2)
Neonatal asphyxia	1 (0.1)	0 (0.0)	1 (0.2)
Pneumothorax	1 (0.1)	0 (0.0)	1 (0.2)
Transient tachypnoea of the newborn	1 (0.1)	1 (0.2)	0 (0.0)
Skin and subcutaneous tissue disorders	1 (0.1)	1 (0.2)	0 (0.0)
Rash	1 (0.1)	1 (0.2)	0 (0.0)
Surgical and medical procedures	6 (0.5)	5 (0.8)	1 (0.2)
Caesarean section	1 (0.1)	1 (0.2)	0 (0.0)
Mechanical ventilation	1 (0.1)	1 (0.2)	0 (0.0)
Patent ductus arteriosus repair	1 (0.1)	0 (0.0)	1 (0.2)
Spinal decompression	1 (0.1)	1 (0.2)	0 (0.0)
Steroid therapy	1 (0.1)	1 (0.2)	0 (0.0)
Surgery	1 (0.1)	1 (0.2)	0 (0.0)
Vascular disorders	2 (0.2)	1 (0.2)	1 (0.2)
Deep-vein thrombosis	1 (0.1)	1 (0.2)	0 (0.0)
Essential hypertension	1 (0.1)	0 (0.0)	1 (0.2)

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:23 2015.

Page 152: *Table 86, Death neonatal* row has been amended as follows:

TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Number of patients, *n*	1183	590	593
Congenital, familial and genetic disorders	10 (0.8)	4 (0.7)	6 (1.0)
Cleft lip and palate	1 (0.1)	0 (0.0)	1 (0.2)
Congenital central nervous system anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Congenital oesophageal anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Cystic fibrosis	1 (0.1)	1 (0.2)	0 (0.0)
Dacryostenosis congenital	1 (0.1)	0 (0.0)	1 (0.2)
Holoprosencephaly	1 (0.1)	0 (0.0)	1 (0.2)
Kidney malformation	1 (0.1)	0 (0.0)	1 (0.2)
Patent ductus arteriosus	2 (0.2)	2 (0.3)	0 (0.0)
Pulmonary artery stenosis congenital	1 (0.1)	1 (0.2)	0 (0.0)
Gastrointestinal disorders	5 (0.4)	5 (0.8)	0 (0.0)
Inguinal hernia	1 (0.1)	1 (0.2)	0 (0.0)
Necrotising colitis	2 (0.2)	2 (0.3)	0 (0.0)
Neonatal necrotising enterocolitis	3 (0.3)	3 (0.5)	0 (0.0)
General disorders and administration site conditions	4 (0.3)	2 (0.3)	2 (0.3)
Adverse drug reaction	1 (0.1)	1 (0.2)	0 (0.0)
Death neonatal	17 (1.4)	8 (1.3)	9 (1.5)
Infections and infestations	11 (0.9)	6 (1.0)	5 (0.8)
Appendicitis	1 (0.1)	1 (0.2)	0 (0.0)
Bronchopneumonia	1 (0.1)	0 (0.0)	1 (0.2)
Infection	1 (0.1)	1 (0.2)	0 (0.0)
Lower respiratory tract infection	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis bacterial	1 (0.1)	1 (0.2)	0 (0.0)
Rash pustular	1 (0.1)	1 (0.2)	0 (0.0)
Sepsis	3 (0.3)	1 (0.2)	2 (0.3)
Urinary tract infection	1 (0.1)	0 (0.0)	1 (0.2)
Wound infection	1 (0.1)	0 (0.0)	1 (0.2)
Injury, poisoning and procedural complications	2 (0.2)	0 (0.0)	2 (0.3)
Post lumbar puncture syndrome	1 (0.1)	0 (0.0)	1 (0.2)
Uterine rupture	1 (0.1)	0 (0.0)	1 (0.2)
Investigations	2 (0.2)	1 (0.2)	1 (0.2)
Fetal heart rate abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Weight decreased	1 (0.1)	1 (0.2)	0 (0.0)

TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Neoplasms benign, malignant and unspecified (including cysts and polyps)	2 (0.2)	1 (0.2)	1 (0.2)
Breast cancer	1 (0.1)	1 (0.2)	0 (0.0)
Teratoma	1 (0.1)	0 (0.0)	1 (0.2)
Nervous system disorders	3 (0.3)	3 (0.5)	0 (0.0)
Cerebral ventricle dilatation	2 (0.2)	2 (0.3)	0 (0.0)
Hydrocephalus	1 (0.1)	1 (0.2)	0 (0.0)
Pregnancy, puerperium and perinatal conditions	56 (4.7)	27 (4.6)	29 (4.9)
Amniorrhexis	1 (0.1)	1 (0.2)	0 (0.0)
Antepartum haemorrhage	6 (0.5)	3 (0.5)	3 (0.5)
Eclampsia	1 (0.1)	1 (0.2)	0 (0.0)
Fetal hypokinesia	1 (0.1)	0 (0.0)	1 (0.2)
Intrauterine death	8 (0.7)	4 (0.7)	4 (0.7)
Jaundice neonatal	1 (0.1)	1 (0.2)	0 (0.0)
Oligohydramnios	1 (0.1)	0 (0.0)	1 (0.2)
Placenta praevia haemorrhage	1 (0.1)	0 (0.0)	1 (0.2)
Post-partum haemorrhage	20 (1.7)	9 (1.5)	11 (1.9)
Premature baby	13 (1.1)	7 (1.2)	6 (1.0)
Premature labour	3 (0.3)	2 (0.3)	1 (0.2)
Premature rupture of membranes	3 (0.3)	1 (0.2)	2 (0.3)
Premature separation of placenta	4 (0.3)	3 (0.5)	1 (0.2)
Retained placenta or membranes	1 (0.1)	0 (0.0)	1 (0.2)
Stillbirth	2 (0.2)	0 (0.0)	2 (0.3)
Threatened labour	1 (0.1)	0 (0.0)	1 (0.2)
Reproductive system and breast disorders	2 (0.2)	0 (0.0)	2 (0.3)
Uterine atony	1 (0.1)	0 (0.0)	1 (0.2)
Vaginal haemorrhage	1 (0.1)	0 (0.0)	1 (0.2)
Respiratory, thoracic and mediastinal disorders	4 (0.3)	1 (0.2)	3 (0.5)
Bronchopulmonary dysplasia	1 (0.1)	0 (0.0)	1 (0.2)
Neonatal asphyxia	1 (0.1)	0 (0.0)	1 (0.2)
Pneumothorax	1 (0.1)	0 (0.0)	1 (0.2)
Transient tachypnoea of the newborn	1 (0.1)	1 (0.2)	0 (0.0)
Surgical and medical procedures	5 (0.4)	4 (0.7)	1 (0.2)
Caesarean section	1 (0.1)	1 (0.2)	0 (0.0)
Mechanical ventilation	1 (0.1)	1 (0.2)	0 (0.0)
Patent ductus arteriosus repair	1 (0.1)	0 (0.0)	1 (0.2)

continued

TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Spinal decompression	1 (0.1)	1 (0.2)	0 (0.0)
Surgery	1 (0.1)	1 (0.2)	0 (0.0)
Vascular disorders	2 (0.2)	1 (0.2)	1 (0.2)
Deep-vein thrombosis	1 (0.1)	1 (0.2)	0 (0.0)
Essential hypertension	1 (0.1)	0 (0.0)	1 (0.2)

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:24 2015.

Page 154: *Table 87, Death neonatal* row has been amended as follows:

TABLE 87 Patients with at least one severe SAE or an SAE with missing severity by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window

Outcome	All patients, *n* (%)	Trial group, *n* (%)	
		Placebo	Progesterone
Number of patients, *n*	1183	590	593
Congenital, familial and genetic disorders	5 (0.4)	0 (0.0)	5 (0.8)
Cleft lip and palate	1 (0.1)	0 (0.0)	1 (0.2)
Congenital central nervous system anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Congenital oesophageal anomaly	1 (0.1)	0 (0.0)	1 (0.2)
Holoprosencephaly	1 (0.1)	0 (0.0)	1 (0.2)
Kidney malformation	1 (0.1)	0 (0.0)	1 (0.2)
Gastrointestinal disorders	3 (0.3)	3 (0.5)	0 (0.0)
Necrotising colitis	2 (0.2)	2 (0.3)	0 (0.0)
Necrotising enterocolitis neonatal	2 (0.2)	2 (0.3)	0 (0.0)
General disorders and administration site conditions	3 (0.3)	1 (0.2)	2 (0.3)
Death neonatal	17 (1.4)	8 (1.3)	9 (1.5)
Infections and infestations	3 (0.3)	2 (0.3)	1 (0.2)
Appendicitis	1 (0.1)	1 (0.2)	0 (0.0)
Meningitis	1 (0.1)	1 (0.2)	0 (0.0)
Sepsis	1 (0.1)	0 (0.0)	1 (0.2)
Injury, poisoning and procedural complications	1 (0.1)	0 (0.0)	1 (0.2)
Uterine rupture	1 (0.1)	0 (0.0)	1 (0.2)
Investigations	1 (0.1)	0 (0.0)	1 (0.2)
Fetal heart rate abnormal	1 (0.1)	0 (0.0)	1 (0.2)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	2 (0.2)	1 (0.2)	1 (0.2)
Breast cancer	1 (0.1)	1 (0.2)	0 (0.0)
Teratoma	1 (0.1)	0 (0.0)	1 (0.2)

TABLE 87 Patients with at least one severe SAE or an SAE with missing severity by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the reporting window (*continued*)

		Trial group, *n* (%)	
Outcome	All patients, *n* (%)	Placebo	Progesterone
Nervous system disorders	1 (0.1)	1 (0.2)	0 (0.0)
Hydrocephalus	1 (0.1)	1 (0.2)	0 (0.0)
Pregnancy, puerperium and perinatal conditions	30 (2.5)	15 (2.5)	15 (2.5)
Amniorrhexis	1 (0.1)	1 (0.2)	0 (0.0)
Antepartum haemorrhage	3 (0.3)	2 (0.3)	1 (0.2)
Eclampsia	1 (0.1)	1 (0.2)	0 (0.0)
Intrauterine death	8 (0.7)	4 (0.7)	4 (0.7)
Oligohydramnios	1 (0.1)	0 (0.0)	1 (0.2)
Postpartum haemorrhage	5 (0.4)	2 (0.3)	3 (0.5)
Premature baby	12 (1.0)	6 (1.0)	6 (1.0)
Premature labour	1 (0.1)	0 (0.0)	1 (0.2)
Premature separation of placenta	2 (0.2)	1 (0.2)	1 (0.2)
Retained placenta or membranes	1 (0.1)	0 (0.0)	1 (0.2)
Stillbirth	2 (0.2)	0 (0.0)	2 (0.3)
Reproductive system and breast disorders	1 (0.1)	0 (0.0)	1 (0.2)
Uterine atony	1 (0.1)	0 (0.0)	1 (0.2)
Respiratory, thoracic and mediastinal disorders	2 (0.2)	0 (0.0)	2 (0.3)
Bronchopulmonary dysplasia	1 (0.1)	0 (0.0)	1 (0.2)
Pneumothorax	1 (0.1)	0 (0.0)	1 (0.2)
Surgical and medical procedures	1 (0.1)	1 (0.2)	0 (0.0)
Spinal decompression	1 (0.1)	1 (0.2)	0 (0.0)
Vascular disorders	1 (0.1)	0 (0.0)	1 (0.2)
Essential hypertension	1 (0.1)	0 (0.0)	1 (0.2)

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:24 2015.

Page 157: *Table 90* has been amended as follows:

TABLE 90 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to risk group

Separate models in each subgroup				
Risk group	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
Low	0.78	0.46 to 1.33	0.361	847
High	0.70	0.37 to 1.31	0.262	329
Interaction model (*n* = 1176)				
Risk group	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
Low	0.78	0.46 to 1.33	0.357	0.786
High	0.69	0.37 to 1.30	0.254	

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:55:04 2015.

Page 159: *Table 95* has been amended as follows:

TABLE 95 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to cervical length at baseline

Separate models in each subgroup				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
> 25	Regression failed			
≤ 25	0.56	0.26 to 1.19	0.133	246
Interaction model (*n* = 682)				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
> 25	0.86	0.42 to 1.77	0.690	0.380
≤ 25	0.54	0.26 to 1.15	0.112	
Model in subgroup with a cervical length of > 25 mm at baseline, not adjusting for previous pregnancy of ≥ 14 weeks' gestation				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
> 25	0.87	0.43 to 1.78	0.706	436

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:55:16 2015.

Page 161: *Table 100* has been amended as follows:

TABLE 100 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to cervical length at baseline

Separate models in each subgroup				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
> 15	0.81	0.44 to 1.51	0.514	588
≤ 15	0.49	0.18 to 1.35	0.168	94
Interaction model (*n* = 682)				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
> 15	0.82	0.44 to 1.52	0.526	0.389
≤ 15	0.49	0.18 to 1.32	0.158	

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:55:24 2015.

Page 164: *Table 105* has been amended as follows:

TABLE 105 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to history of spontaneous preterm birth

Separate models in each subgroup				
Cervical length at baseline (mm)	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
No	1.24	0.55 to 2.82	0.601	270
Yes	Regression failed			
Interaction model (*n* = 1156)				
History of spontaneous preterm birth	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
No	1.23	0.54 to 2.77	0.623	0.0135
Yes	0.60	0.37 to 0.96	0.033	
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks' gestation				
History of spontaneous preterm birth	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
Yes	0.68	0.37 to 0.96	0.034	887

Note
OPPTIMUM Output created by OPPTIMUM_additional03_v1_0.R.R Last run on Tue Feb 16 15:08:47 2016.

Page 166: *Table 110* has been amended as follows:

TABLE 110 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to history of preterm birth

Separate models in each subgroup				
History of preterm birth	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
No	1.11	0.48 to 2.57	0.802	248
Yes	Regression failed			
Interaction model (*n* = 1175)				
History of preterm birth	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
No	1.09	0.47 to 2.52	0.836	0.263
Yes	0.63	0.40 to 1.00	0.052	
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks' gestation				
History of spontaneous preterm birth	**OR**	**95% CI**	***p*-value**	***n***
Yes	0.64	0.40 to 1.01	0.054	928

Note
OPPTIMUM Output created by OPPTIMUM_additional03_v1_0.R.R Last run on Tue Feb 16 15:08:59 2016.

Page 169: *Table 115* has been amended as follows:

TABLE 115 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and site as a random effect in subgroups according to chorioamnionitis diagnosed on pathology

Separate models in each subgroup				
Chorioamnionitis diagnosed on pathology	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
No	Regression failed			
Yes	2.53	0.75 to 8.59	0.141	56
Interaction model ($n = 171$)				
Chorioamnionitis diagnosed on pathology	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
No	1.81	0.30 to 4.68	0.810	0.429
Yes	2.53	0.71 to 9.06	0.156	
Model in subgroup without chorioamnionitis, not adjusting for previous pregnancy of ≥ 14 weeks' gestation				
Chorioamnionitis diagnosed on pathology	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
No	1.16	0.28 to 4.80	0.841	115

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:55:56 2015.

Page 171: *Table 120* has been amended as follows:

TABLE 120 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease in subgroups according to previous pregnancy of ≥ 14 weeks' gestation

Separate models in each subgroup				
Previous pregnancy of ≥ 14 weeks' gestation	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***n***
No	6.64	0.70 to 62.89	0.103	73
Yes	0.64	0.42 to 0.97	0.035	1104
Interaction model ($n = 1176$)				
Previous pregnancy of ≥ 14 weeks' gestation	**OR (progesterone vs. placebo)**	**95% CI**	***p*-value**	***p*-value for interaction**
No	6.19	0.68 to 56.24	0.106	0.048
Yes	0.64	0.42 to 0.97	0.035	

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:56:09 2015.

Page 186: *Table 137* has been amended as follows:

TABLE 137 Mixed effects logistic regression model for the effect of treatment on the primary neonatal outcome death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks' gestation and study centre as a random effect (PP population)

Parameter	OR	95% CI	*p*-value
Treatment (progesterone vs. placebo)	0.63	0.35 to 1.15	0.113
Previous pregnancy ≥ 14 weeks' gestation	1.41	0.42 to 4.76	0.583
n = 682			

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 20 11:27:20 2015.

Page 187: *Table 141, Neonatal outcome* row has been amended as follows:

TABLE 141 Sensitivity analysis: multiple imputation of primary outcomes

Outcome	Parameter estimate or hazard ratio	95% CI	*p*-value
Variables used for predicting outcome: previous pregnancy of ≥ 14 weeks' gestation, high/low risk, maternal age and sex			
Obstetric outcome	0.866	0.640 to 1.170	0.348
Neonatal outcome	0.728	0.487 to 1.088	0.112
Variables used for predicting outcome: gestational age, birth weight, chronic lung disease, brain injury, previous pregnancy of ≥ 14 weeks' gestation, high/low risk, maternal age and sex			
Alive at 2 years	0.760	0.392 to 1.476	0.418
Bayley III cognitive composite score	–0.019	–0.372 to 0.334	0.908
Variables used for predicting outcome: birth weight, chronic lung disease, brain injury, previous pregnancy of ≥ 14 weeks' gestation, high/low risk, maternal age and sex			
Alive at 2 years	0.744	0.384 to 1.441	0.380
Bayley III cognitive composite score	–0.051	–0.371 to 0.269	0.737

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 20 11:27:38 2015.

Page 194: *Table 152, Neonatal deaths (excluding fetal deaths)* and *Neonatal or fetal death* rows have been amended as follows:

TABLE 152 Logistic regression models for the effect of treatment on secondary outcomes adjusted for previous pregnancies of ≥ 14 weeks' gestation

Outcome	*n*	OR	95% CI	*p*-value
Fetal death	1197	1.14	0.41 to 3.17	0.802
Fetal death before 34 weeks' gestation	1197	1.16	0.39 to 3.49	0.786
Delivery before 34 weeks' gestation (excluding deaths before 34 weeks' gestation)	1184	0.85	0.62 to 1.15	0.292
Neonatal deaths (excluding fetal deaths)[a]	1182	1.14	0.44 to 2.98	0.79
Neonatal or fetal death	1197	1.13	0.56 to 2.29	0.728
Necrotising enterocolitis (suspected or treated)	1155	1.37	0.76 to 2.45	0.291
Any episode of infection with positive blood culture vs. no infection or infection without positive blood culture	1147	0.87	0.49 to 1.56	0.642
Any episode of infection with positive blood or cerebrospinal fluid culture vs. no infection or infection without positive blood or cerebrospinal fluid culture	1147	0.92	0.52 to 1.65	0.789

a Not adjusted for previous pregnancy of ≥ 14 weeks' gestation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:46 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility of error remains.

Page 197: *Table 156, Neonatal* row has been amended as follows:

TABLE 156 Adjusted CI using Bonferroni–Holm adjustment

Outcome	95% CI
Obstetric	0.61 to 1.22
Neonatal	0.44 to 1.17

Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:38 2015.

Reference

1. Norman JE, Marlow N, Messow C-M, Shennan A, Bennett PR, Thornton S, *et al.* Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM), *Health Technol Assess* 2018;**22**(35).